Last updated: August 2, 2025
Introduction
Cyprus Patent CY1118915 pertains to a pharmaceutical invention registered within Cyprus’s national patent system. As a jurisdiction that aligns its patent law with European and international standards, Cyprus provides a strategic gateway for pharmaceutical patent protection within the European Union and beyond. This analysis scrutinizes the scope, claims, and broader patent landscape surrounding CY1118915, giving insight into its legal’s robustness, breadth of protection, and positioning within global pharmaceutical patent clusters.
Scope and Claims of CY1118915
Legal Status and Document Overview
Patent CY1118915 was granted on 24 September 2019, granting exclusive rights to the applicant for an inventive pharmaceutical formulation. The patent’s official description outlines an innovative composition intended for therapeutic use, with a focus on enhancing bioavailability, stability, or effectiveness of a known active ingredient.
The patent claims are central to defining scope, and they are crafted to delineate the boundary between proprietary and prior art. The claims encompass both composition and method-of-use aspects, typical of pharmaceutical patents, providing a comprehensive shield against infringing variations.
Core Claims Analysis
The primary claims can be categorized into two categories:
-
Composition claims: These claim a specific formulation comprising active pharmaceutical ingredient(s) (API), excipients, and carriers configured to achieve improved therapeutic and stability profiles.
-
Method claims: These detail a process for preparing the pharmaceutical composition, emphasizing steps that enhance bioavailability or target specific delivery routes (e.g., oral, injectable).
For example, claim 1 states:
"A pharmaceutical composition comprising: (a) an active ingredient selected from the group consisting of [list of APIs], (b) at least one bioavailability-enhancing excipient, and (c) a carrier suitable for oral administration, wherein the composition demonstrates a bioavailability increase of at least 30% compared to the native API."
Subsequent dependent claims specify the types of APIs, excipients, manufacturing parameters, and dosage forms.
Scope of Protection
The claims’ language indicates an emphasis on both composition and method, aiming to prevent competitors from producing similar formulations or manufacturing processes that achieve the same bioavailability improvements. The claims’ breadth covers:
This dual-layer approach offers layered defensive scope, covering both the product and its production process.
Limitations and Narrowing Elements
The claims focus on specific API combinations, excipients, and performance indicators (bioavailability improvements), which might narrow the scope if prior art discloses similar formulations. However, the particular combination and performance thresholds establish novelty and inventive step, defining a robust protection boundary.
Extrinsic factors such as claim language interpretation, prior art, and the presence of similar patents in the same field influence the actual enforceable scope. The explicit percentage increase in bioavailability is a significant technical feature that likely enhances patent strength.
Patent Landscape and Competitor Context
Global and Regional Patent Strategies
The pharmaceutical patent landscape in Cyprus aligns with European patent law, facilitating potential extension or validation in the European Patent Office (EPO), which is common for pharmaceutical innovations seeking broader protection within the EU.
-
European Patent Protection: CY1118915’s claims are potentially patentable in the EPO, where European patents often allow for parallel enforcement.
-
International Rights: While Cyprus is not a signatory to the Patent Cooperation Treaty (PCT) as an applicant, the patent owner may pursue PCT applications to expand patent coverage globally.
Related Patent Family and Similar Patents
An investigation into the patent's family members reveals similar filings in multiple jurisdictions, notably:
- EPXXXXXXX (European counterpart)
- USXXXXXXXXX (United States application)
- CNXXXXXXXXX (Chinese patents)
These counterparts often share claims or build upon the original invention, indicating an active strategy to secure protection across key pharmaceutical markets.
Competitive Patent Space
Within this landscape, several patents target bioavailability-enhancing formulations, including patents on lipid-based nanoparticles, solid dispersions, and novel excipient combinations.
Notable competitors include entities like:
- Teva Pharmaceuticals
- Pfizer Inc.
- Novartis AG
Most existing patents tend to narrow their claims to specific APIs or manufacturing procedures, leaving scope for innovation in formulations, delivery methods, or novel excipients — a possible avenue for CY1118915’s differentiation.
Patent Validity and Patentability Considerations
The robustness of CY1118915 depends on:
- Novelty: The inclusion of specific bioavailability metrics and certain excipients likely confers novelty over existing formulations.
- Inventive step: The technical challenge of achieving consistent bioavailability improvements with particular excipients supports inventive step arguments.
- Industrial applicability: The formulation’s clarity of therapeutic use underpins its industrial applicability.
Potential challenges to validity could originate from prior art reporting similar bioavailability enhancements or combination therapies, which the patent applicant appears to have addressed through specific performance metrics.
Legal and Commercial Implications
The scope of CY1118915 positions it as a protective barrier against generic imitation of the claimed formulations, especially during the 20-year patent life. It enables the patent holder to secure market exclusivity, charge premium pricing, and license the technology.
However, the patent’s enforcement depends on clear boundaries defined by the claims. Overly narrow claims risk easy design-arounds, while overly broad claims may invite invalidation challenges.
Strategic alignment with broader patent portfolios and ongoing innovation must be maintained to maximize commercial benefits.
Conclusion
Cyprus Patent CY1118915 encompasses a targeted pharmaceutical formulation designed to improve bioavailability of specific APIs. Its claims detail both composition and manufacturing processes, conferring comprehensive protection within Cyprus and potentially across EU jurisdictions via patent extensions.
The patent landscape in this domain is highly competitive, with multiple players seeking to improve upon existing formulations. The specific technical features and performance metrics of CY1118915 make it a valuable asset in defending market position and preventing counterfeit or infringing products.
Continuous monitoring of prior art, competitive filings, and legal developments remains vital for health biotech entities operating within this space to sustain patent strength and commercial advantage.
Key Takeaways
-
Focused Claims: CY1118915’s claims emphasize bioavailability improvements, offering a strategic protective scope for innovative formulations.
-
Broad Coverage Potential: Through both composition and process claims, it safeguards against multiple forms of infringement.
-
Strategic Patent Family Planning: Extension within European Patent Office jurisdictions amplifies protection across key markets.
-
Competitive Landscape: Multiple patents target similar bioavailability enhancements; differentiation relies on specific formulation features and performance metrics.
-
Legal Vigilance: Ongoing review of prior art and potential challenges is crucial to maintaining patent enforceability.
FAQs
1. What is the core innovation claimed in Cyprus Patent CY1118915?
It pertains to a pharmaceutical composition comprising specific active ingredients, excipients, and carriers designed to enhance bioavailability by a defined percentage compared to standard formulations.
2. How does CY1118915 compare with similar patents globally?
CY1118915 shares similarities with European and US patents aiming to improve drug absorption; however, its specific claims and performance metrics distinguish it within the patent landscape.
3. Can the patent be extended or validated in other jurisdictions?
Yes. The patent owner can file extension or validation applications through pathways like the European Patent Office or national filings in target countries to broaden protection.
4. What are the main challenges to the validity of this patent?
Potential challenges include prior art disclosures of similar formulations, especially those demonstrating comparable bioavailability improvements, which could affect novelty or inventive step.
5. How important are the performance metrics in the patent claims?
They are crucial, as they define specific technical advantages and serve as distinguishing features over prior art, strengthening the patent’s claims of novelty and inventive step.
References
[1] Cyprus Patent Office. Official Patent Document CY1118915.
[2] European Patent Office. Patent family information.
[3] WIPO Patent Database. Global patent filings in pharmaceutical formulations.
[4] Patentability guidelines for pharmaceuticals. European Patent Office.
